Prediction of response to hormonal treatment in metastatic breast cancer

Oncology

Volumn 63, Issue 4, 2002, Pages 309-316

  Schmid, Peter ^c   Wischnewsky, M B ^a   Sezer, O ^d   Bohm R ^b   Possinger, K ^d  

^a UNIVERSITY OF BREMEN   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c HUMBOLDT UNIVERSITY   (Germany)

^d NONE

Author keywords

Artificial neural networks; Breast cancer; Classification model; Hormone treatment; Predictive parameter

Indexed keywords

HORMONE; HORMONE RECEPTOR; LETROZOLE;

ALGORITHM; ARTIFICIAL NEURAL NETWORK; BONE METASTASIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER PATIENT; DATA BASE; ENTROPY; HUMAN; MATHEMATICAL MODEL; METASTASIS; ONCOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOFT TISSUE METASTASIS; VISCERAL METASTASIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DECISION TREES; HUMANS; NEOPLASM METASTASIS; NEURAL NETWORKS (COMPUTER); PROPORTIONAL HAZARDS MODELS;

EID: 0345382856     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066224     Document Type: Review

References (15)

1. Sedlacek SM, Horowitz KB: The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids 1994;44:467-484.
2. Spataro V, Price K, Goldhirsch A, Cavalli F, Simoncini E, Castiglione M, Rudenstam CM, Collins J, Lindtner J, Gelber RD: Sequential estrogen receptor determination from primary breast cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992;3:733-740.
3. Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B: Prognostic value of steroid receptors after long-term follow-up of 2,257 operable breast cancers. Br J Cancer 1996;73:1545-1551.
4. Broet P, Pichon MF, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B: Long-term prognostic role of steroid receptors in cancer of the breast. Bull Cancer 1998;85:347-352.
5. Wischnewsky MB, Schmid P, Böhm R, Chaudri HA, Possinger K: Who benefits most from second-line treatment with letrozole? In Miller WR, Santen RJ (eds): Aromatase Inhibition and Breast Cancer. New York, Dekker, 2000, pp 63-85.
6. Ripley BD: Statistical aspects of neural networks; in Barndorff-Nielsen OE, et al (eds): Chaos and Networks - Statistical and Probabilistic Aspects. London, Chapman & Hall, 1993.
7. Schmid P, Possinger K, Böhm R, Chaudri HA, Verbeek A, Grosse Y, Lüftner D, Petrides PE, Sezer O, Wischnewsky MB: Body mass index as predictive parameter for response and time to progression in advanced breast cancer patients treated with letrozole or megestrol acetate. Proc Am Soc Clin Oncol 2000;18:abstr 398.
8. Possinger K, Schmid P, Böhm R, Chaudri HA, Sezer O, Wischnewsky MB: Letrozole in ABC patients with visceral metastases. Proc Am Soc Clin Oncol 2000;18:abstr 397.
9. Wischnewsky MB, Schmid P, Böhm R, Chaudri HA, Grunewald R, Possinger K: Classification of patients with long times to treatment failure and overall survival having stable disease under second-line treatment with letrozole or MA. Proc Am Soc Clin Oncol 2000;18:abstr 508.
10. Wischnewsky MB, Schmid P, Boehm R, Verbeek JA, Possinger K: Letrozole and megestrole acetate in patients with advanced breast cancer resistant to taxmoxifen. Breast Cancer Res Treat 2000;64:54.
11. Possinger K, Schmid P, Wischnewsky MB: Letrozole is highly effective in patients with soft tissue metastases. Breast Cancer Res Treat 2000;64:53.
12. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-461.
13. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P, Lassus M: Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group. Ann Oncol 1998;9:639-645.
14. Wischnewsky MB, Schmid P, Possinger K: Self-organizing maps for data analysis and prediction of outcome in second-line hormonal treatment of metastatic breast cancer. Ann Oncol 2000;11(suppl 4):25.
15. Schmid P, Possinger K, Wischnewsky MB: Self-organizing maps and prognosis of advanced breast cancer patients with bone metastases receiving letrozole or MA. Breast Cancer Res Treat 2000;64:77.